STAT3-induced S1PR1 Expression is Crucial for Persistent STAT3 Activation in Tumors

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2010 Nov 25

PMID 21102457

Citations 224

Authors

Heehyoung Lee

Jiehui Deng

Maciej Kujawski

Chunmei Yang

Yong Liu

Andreas Herrmann

Marcin Kortylewski

David Horne

George Somlo

Stephen Forman

Richard Jove

Hua Yu

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6)-Janus kinase (JAK) signaling is viewed as crucial for persistent signal transducer and activator of transcription-3 (STAT3) activation in cancer. However, IL-6-induced STAT3 activation is normally transient. Here we identify a key mechanism for persistent STAT3 activation in tumor cells and the tumor microenvironment. We show that expression of sphingosine-1-phosphate receptor-1 (S1PR1), a G protein-coupled receptor for the lysophospholipid sphingosine-1-phosphate (S1P), is elevated in STAT3-positive tumors. STAT3 is a transcription factor for the S1pr1 gene. Reciprocally, enhanced S1pr1 expression activates STAT3 and upregulates Il6 gene expression, thereby accelerating tumor growth and metastasis in a STAT3-dependent manner. Silencing S1pr1 in tumor cells or immune cells inhibits tumor STAT3 activity, tumor growth and metastasis. S1P-S1PR1-induced STAT3 activation is persistent, in contrast to transient STAT3 activation by IL-6. S1PR1 activates STAT3 in part by upregulating JAK2 tyrosine kinase activity. We show that STAT3-induced S1PR1 expression, as well as the S1P-S1PR1 pathway reciprocal regulation of STAT3 activity, is a major positive feedback loop for persistent STAT3 activation in cancer cells and the tumor microenvironment and for malignant progression.

Citing Articles

Local CpG- siRNA treatment improves antitumor effects of immune checkpoint inhibitors.

Zhang C, Huang R, Ren L, Martincuks A, Song J, Kortylewski M Mol Ther Nucleic Acids. 2024; 35(4):102357.

PMID: 39618825 PMC: 11605413. DOI: 10.1016/j.omtn.2024.102357.

S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.

Chai Y, Xiang H, Ma Y, Feng W, Jiang Z, Zhu Q J Exp Clin Cancer Res. 2024; 43(1):304.

PMID: 39551792 PMC: 11571582. DOI: 10.1186/s13046-024-03230-5.

Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways.

Khan F, Elsori D, Verma M, Pandey S, Rab S, Siddiqui S Front Cell Dev Biol. 2024; 12:1399065.

PMID: 38933330 PMC: 11199418. DOI: 10.3389/fcell.2024.1399065.

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype.

Ding H, Wang H, Wu D, Zhou F, Zhu J, Tong J Mol Med Rep. 2024; 30(2).

PMID: 38873983 PMC: 11200052. DOI: 10.3892/mmr.2024.13261.

Advances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review).

Wang Z, Chang Y, Sun H, Li Y, Tang T Oncol Lett. 2024; 27(6):257.

PMID: 38646499 PMC: 11027113. DOI: 10.3892/ol.2024.14390.

References

Rosen H, Goetzl E . Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005; 5(7):560-70. DOI: 10.1038/nri1650. View

Hedvat M, Huszar D, Herrmann A, Gozgit J, Schroeder A, Sheehy A . The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16(6):487-97. PMC: 2812011. DOI: 10.1016/j.ccr.2009.10.015. View

Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T . gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15(2):91-102. DOI: 10.1016/j.ccr.2009.01.002. View

Halak B, MAGUIRE Jr H, Lattime E . Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999; 59(4):911-7. View

Pappu R, Schwab S, Cornelissen I, Pereira J, Regard J, Xu Y . Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007; 316(5822):295-8. DOI: 10.1126/science.1139221. View

Shiow L, Rosen D, Brdickova N, Xu Y, An J, Lanier L . CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006; 440(7083):540-4. DOI: 10.1038/nature04606. View

Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M . In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009; 27(10):925-32. PMC: 2846721. DOI: 10.1038/nbt.1564. View

Carlson C, Endrizzi B, Wu J, Ding X, Weinreich M, Walsh E . Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature. 2006; 442(7100):299-302. DOI: 10.1038/nature04882. View

Sabbadini R . Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer. 2006; 95(9):1131-5. PMC: 2360571. DOI: 10.1038/sj.bjc.6603400. View

10.

Matloubian M, Lo C, Cinamon G, Lesneski M, Xu Y, Brinkmann V . Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427(6972):355-60. DOI: 10.1038/nature02284. View

11.

Zhong Z, Wen Z, Darnell Jr J . Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994; 264(5155):95-8. DOI: 10.1126/science.8140422. View

12.

Wang L, Yi T, Kortylewski M, Pardoll D, Zeng D, Yu H . IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009; 206(7):1457-64. PMC: 2715087. DOI: 10.1084/jem.20090207. View

13.

Visentin B, Vekich J, Sibbald B, Cavalli A, Moreno K, Matteo R . Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-38. DOI: 10.1016/j.ccr.2006.02.023. View

14.

Igarashi J, Erwin P, Dantas A, Chen H, Michel T . VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci U S A. 2003; 100(19):10664-9. PMC: 196861. DOI: 10.1073/pnas.1934494100. View

15.

Yu C, Meyer D, Campbell G, Larner A, Schwartz J, Jove R . Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995; 269(5220):81-3. DOI: 10.1126/science.7541555. View

16.

Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

17.

Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

18.

Schwab S, Cyster J . Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007; 8(12):1295-301. DOI: 10.1038/ni1545. View

19.

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

20.

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View